FindTrial
Sign In

A Phase II Study of Induction with Immunotherapy, Targeted Therapy, and Chemotherapy, Followed by Maintenance with Immunotherapy, Targeted Therapy, and a PARP Inhibitor in Platinum-Resistant Ovarian Cancer

A Single-Arm, Prospective Phase II Clinical Study of Adebrelimab Combined with Apatinib and Chemotherapy, Followed by Adebrelimab Plus Apatinib and Fluozoparib as Maintenance Therapy in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111250
Enrollment
Unknown
Registered
2025-10-28
Start date
2025-10-28
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Platinum-resistant recurrent ovarian cancer

Interventions

Platinum-resistant recurrent ovarian cancer:Induction with adebrelimab, apatinib, and chemotherapy, followed by maintenance with adebrelimab, apatinib, and fluzoparib.

Sponsors

First Hospital Of Nanping
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. 2. Disease recurrence within 6 months after completion of first-line platinum-based chemotherapy. 3. ECOG performance status of 0 to 2. 4. At least one measurable lesion. 5. The patient (or subject) has voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Uncontrolled hypertension and cardiac dysfunction (NYHA class III-IV) . 2. Myocardial infarction or stroke within the past 6 months. 3. Active infection, immunodeficiency, or requirement for long-term immunosuppressive therapy. 4. Severe hepatic/renal dysfunction (ALT/AST >3×ULN, Cr >1.5×ULN) and other risk factors. 5. Major surgery within 6 weeks. 6. Hypersensitivity or contraindications to any component of the investigational drug.

Design outcomes

Primary

MeasureTime frame
Objective Response Rate(ORR);—

Secondary

MeasureTime frame
Progression Free Survival, PFS;—

Countries

China

Contacts

Public ContactRenliang Fan

First Hospital Of Nanping

523221402@qq.com+86 599 860 5951

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026